Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at B. Riley decreased their Q2 2025 EPS estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of ($0.86) per share for the quarter, down from their previous estimate of ($0.80). B. Riley currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics' Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($2.52) EPS and FY2029 earnings at $0.27 EPS.
Several other analysts also recently weighed in on the stock. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Wedbush dropped their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective on the stock. Robert W. Baird dropped their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Finally, HC Wainwright decreased their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $33.79.
Get Our Latest Stock Report on Denali Therapeutics
Denali Therapeutics Stock Down 2.1%
Shares of NASDAQ DNLI traded down $0.30 during trading hours on Monday, hitting $13.96. 1,170,551 shares of the stock were exchanged, compared to its average volume of 1,095,969. The company has a market cap of $2.03 billion, a PE ratio of -5.06 and a beta of 1.49. The firm has a fifty day moving average price of $14.20 and a 200-day moving average price of $19.87. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the company posted ($0.68) EPS.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in DNLI. Caitong International Asset Management Co. Ltd increased its stake in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after acquiring an additional 1,551 shares during the last quarter. Sterling Capital Management LLC increased its holdings in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Denali Therapeutics in the first quarter valued at approximately $41,000. GF Fund Management CO. LTD. acquired a new stake in Denali Therapeutics during the fourth quarter worth $62,000. Finally, Point72 Hong Kong Ltd purchased a new stake in Denali Therapeutics in the fourth quarter valued at $65,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.
Denali Therapeutics Company Profile
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
See Also
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
